Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The aim of the study was to compare the modulatory effects of 17beta-estradiol and raloxifene, a selective estrogen receptor modulator, on the metabolic action of GH.

Why It Was Studied

The metabolic action of GH is attenuated by estrogens administered via the oral route.

Selective estrogen receptor modulators lower IGF-I to a lesser degree than 17beta-estradiol in GH-deficient women, and their effect on fat and protein metabolism is unknown.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, women only.

The treatment duration was 1 month, with a 4-wk washout period.

How the Study Was Run

The researchers set it up as a randomized, open-label and crossover study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

The researchers conducted an open-label, two-group, randomized, two-period crossover study.

What Was Measured

Topics PubMed links to this paper include Calorimetry, Indirect, Estradiol, Estrogen Replacement Therapy, Human Growth Hormone, Hypopituitarism, Insulin-Like Growth Factor Binding Protein 3 and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.